ArticleClinical proteomics2025
Proteome profiling of cerebrospinal fluid-derived extracellular vesicles reveals potential biomarkers for drug-resistant epilepsy.
Article in Clinical proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEpilepsy is one of the most common neurological disorders in humans and in dogs. Treatment currently focuses on alleviating symptoms, and a wide range of anti-seizure medications (ASMs) is available. Still, over one-third of patients have an inadequate response to ASM. The proteome of cerebrospinal fluid (CSF)-derived extracellular vesicles (EVs) offers a potential source of biomarkers for drug-resistant epilepsy (DRE).
methodsWe utilised a spontaneous canine epilepsy model to study the proteomic content of CSF-derived EVs as a source of biomarkers for DRE. We included 37 drug-naïve dogs with recent onset epilepsy and confirmed diagnosis of idiopathic epilepsy. CSF samples were collected at the onset of epilepsy. After the first visit, ASM treatment was started in all dogs and they were followed up for at least 12 months. After the follow-up period, based on their response to ASM treatment, dogs were grouped as either drug-responsive or drug-resistant. We isolated CSF-derived EVs with ultrafiltration combined with size-exclusion chromatography and then performed proteomic analysis with liquid chromatography-tandem mass spectrometry. A comparison between the drug-responsive and drug-resistant dogs was conducted regarding clinical factors and CSF-derived EV proteomic data.
resultsYounger age at seizure onset and occurrence of cluster seizures were identified as risk factors for drug-resistance. The proteomic analysis of normalised data identified five proteins with differential abundance between the two groups: KRT4, an uncharacterised immunoglobulin-like domain-containing protein (IgDCPa), F2, DSC1b, and LOC607874. A receiver operating characteristic analysis was performed, revealing a predictive value of ≥ 0.90 for two combinations of three proteins (KRT4, IgDCPa, and F2 (area under curve (AUC) = 0.91, confidence interval (CI) = 0.78-1.00); DSC1b, F2, and IgDCPa (AUC = 0.90, CI = 0.78-1.00)).
conclusionsProteins with differential abundance studied here are associated with epilepsy due to their potential involvement in critical processes such as neuroprotection, inflammation, cell integrity, and immune response. The observed reduction in the abundance of these proteins in drug-resistant dogs suggests that disruptions in these processes may contribute to the severity of the condition and its resistance to treatment. Results from this pilot study warrant further study in a larger cohort.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.